Shionogi Wins Japan Approval for Rapid-Acting Depression Drug ZURZUVAE

An announcement from Shionogi & Co ( (JP:4507) ) is now available.

Shionogi has received Japanese regulatory approval to manufacture and market ZURZUVAE Capsules 30 mg (zuranolone) for the treatment of depression and depressive states, following positive Phase 3 trial results in adults with major depressive disorder. The novel oral GABA-A receptor modulator demonstrated rapid symptom improvement, sustained efficacy and safety over a 14-day dosing regimen, and effectiveness upon re-treatment after a drug-free interval, positioning it to address a significant unmet need in Japan, where an estimated 5 million people live with depression and many existing antidepressants have slow onset of action. By adding ZURZUVAE to its central nervous system portfolio, Shionogi aims to help shift the treatment paradigm in depression and reinforce its strategic goal of contributing to longer, healthier, and more fulfilling lives, potentially strengthening its presence in mental health therapeutics and its competitiveness in the CNS drug market.

The most recent analyst rating on (JP:4507) stock is a Buy with a Yen3015.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.

More about Shionogi & Co

Shionogi & Co., Ltd. is a leading global research-driven pharmaceutical company headquartered in Osaka, Japan, focused on discovering and developing innovative medicines. The company has a strong track record in antibiotics and treatments for HIV and influenza, and currently markets therapies for infectious diseases and central nervous system disorders, supported by a global pipeline spanning infectious disease, pain/CNS, metabolic disorders, rare diseases, oncology and stroke.

YTD Price Performance: 25.72%

Average Trading Volume: 2,760,066

Technical Sentiment Signal: Buy

Current Market Cap: Yen2388.8B

For detailed information about 4507 stock, go to TipRanks’ Stock Analysis page.